Vanguard Capital Management
NNVC icon

Vanguard Capital Management’s NanoViricides NNVC Stock Holding History

Vanguard Capital Management’s Portfolio NNVC Stock Details NNVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
919,313
+407,836
+80% +$559K ﹤0.01% 3543
2026
Q1 		$466K Buy
+511,477
New +$535K ﹤0.01% 3684

Other funds holding NNVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's NNVC Position: Q2 2026 in Review

Vanguard Capital Management increased its NanoViricides (NNVC) stake by 80% in Q2 2026, buying an estimated $559K and bringing the position to 919,313 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

Vanguard Capital Management first reported a position in NNVC in Q1 2026 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold NNVC as of Q2 2026.

  • Vanguard Capital Management held 919,313 shares of NanoViricides worth $1.27M as of Q2 2026.
  • Vanguard Capital Management bought 407,836 NanoViricides shares in Q2 2026, an estimated $559K.
  • NanoViricides made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3543 holding.
  • Vanguard Capital Management first reported a position in NanoViricides in Q1 2026 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held NanoViricides as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.